• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Genzyme

Genzyme

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

    Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

  2. REITs, Target Dates, Dollar-Proofing, and More

    A roundup of investment news.

  3. High-Confidence Stock Picks

    Focusing on stocks with the most visible cash flows has been a winning strategy, and this screen can find them.

  4. Early Favorites for Manager of the Year--Domestic Stock

    Who's in front heading 'round the bend?

  5. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  6. Back to Basics

    This screen finds stocks that would make it into Morningstar's Wide-Moat Focus strategy.

  7. Tech Stock Rally Leaves Some Funds Behind

    Plus, Vanguard says 401(k) investors stayed the course in 2008, Macquarie Group buys Delaware Investments, more leveraged ETF warnings, and more.

  8. Funds Betting on Apple, Google, and RIM

    Many funds' fortunes have turned amid these stocks' volatility.

  9. Sanofi Shakes Off Patent Losses

    The drugmaker faces less long-term volatility as the focus shifts to steady businesses.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.